Patent · US Active

CFTR mRNA compositions and related methods and uses

US9713626B2 · kind B2 · utility

11Cited by

247References

19Claims

0Family size

Assignees

RaNA Therapeutics, Inc. · US
ethris GmbH · DE

Inventors

Michael Heartlein · Boxborough, US
Braydon Charles Guild · Concord, US
Frank DeRosa · Lexington, US
Carsten Rudolph · Krailling, DE
Christian Plank · Wien, AT
Lianne Smith · Lexington, US

Key dates

Filing date	Oct 6, 2015
Grant date	Jul 25, 2017
Priority date	—
Expiry date	Oct 6, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y306/03049
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Pharmaceutical compositions comprising an mRNA-loaded nanoparticle, wherein the mRNA is an in vitro transcribed mRNA and has a coding sequence at least 80% identical to SEQ ID NO: 3, and wherein the mRNA encodes a human cystic fibrosis transmembrane conductance regulator (CFTR) protein comprising the amino acid sequence of SEQ ID NO:1 are provided. The present invention is particularly useful for treating cystic fibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.